EPISODE · Apr 22, 2022 · 32 MIN
#43 Impact Careers: BioMagnetic Solutions, A Penn State Partner in Cancer Research
from Smeal Lifelong Learning Podcast · host Smeal College of Business
The market for clinical cell selection will reach $1 billion by 2030. Tune in as Smeal alumnus Ted Liberti ’03 M.S., CBO of BioMagnetic Solutions, discusses how his biotech startup's magnetic cell selection technology gives companies the tools to create cures for cancer as cell & gene therapy companies make genetically-engineered CAR-T cells for patients - the future of biotechnology. He discusses how and why he chose to bring his business to State College, and how his company is partnering with Penn State on this important research. #WeAre"If successful, CAR-T cell and gene therapies (CGT) products are a one & done treatment/Tx/therapy that lives, endures, and continues to deliver its benefits long term, providing bona fide cures in some cases – a word oncologists never use lightly.” –Ted Liberti
What this episode covers
The market for clinical cell selection will reach $1 billion by 2030. Tune in as Smeal alumnus Ted Liberti ’03 M.S., CBO of BioMagnetic Solutions, discusses how his biotech startup's magnetic cell selection technology gives companies the tools to create cures for cancer as cell & gene therapy companies make genetically-engineered CAR-T cells for patients - the future of biotechnology. He discusses how and why he chose to bring his business to State College, and how his company is partnering with Penn State on this important research. #WeAre"If successful, CAR-T cell and gene therapies (CGT) products are a one & done treatment/Tx/therapy that lives, endures, and continues to deliver its benefits long term, providing bona fide cures in some cases – a word oncologists never use lightly.” –Ted Liberti
NOW PLAYING
#43 Impact Careers: BioMagnetic Solutions, A Penn State Partner in Cancer Research
No transcript for this episode yet
Similar Episodes
Mar 26, 2026 ·1m
Jan 2, 2026 ·47m
Dec 21, 2025 ·46m